SCHEDULE: Alphabet-Backed GV Discloses 2.9% Stake in Maze Therapeutics

Alphabet Inc. and its venture capital arm, GV, have disclosed a 2.9% beneficial ownership stake in Maze Therapeutics, Inc. through a Schedule 13G amendment.

Summary

• Reporting persons, including GV 2019, L.P., GV 2023, L.P., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively beneficially own 1,388,583 shares of Maze Therapeutics, Inc. Common Stock.
• This aggregate ownership represents 2.9% of Maze Therapeutics' outstanding Common Stock.
• The ownership is split between GV 2019, L.P., which directly owns 784,019 shares (1.6%), and GV 2023, L.P., which directly owns 604,564 shares (1.3%).
• Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. are deemed to indirectly beneficially own all 1,388,583 shares due to their control over the GV entities.
• The percentages were calculated based on 48,119,444 shares of Common Stock outstanding as of November 3, 2025, as reported by Maze Therapeutics in its Quarterly Report on Form 10-Q filed on November 6, 2025.
• All reporting persons are formed, organized, or incorporated in the State of Delaware.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued, passive institutional investment by a reputable venture capital firm (GV, backed by Alphabet Inc.) in Maze Therapeutics.

Positives

• Continued investment by Alphabet-backed GV entities signals ongoing interest in Maze Therapeutics.
• The disclosure of a significant, albeit passive, stake by a prominent institutional investor group can enhance market visibility and credibility for Maze Therapeutics.

Negatives

• The 2.9% stake is below the 5% threshold typically associated with more active investor influence or significant strategic interest, indicating a passive investment.

Risks

• The filing itself does not detail specific risks related to Maze Therapeutics' operations or financial health; it is solely an ownership disclosure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for passive investors holding between 5% and 20% of a company's stock, or for certain institutional investors holding less than 5% but meeting specific criteria. This filing, an amendment, indicates a continued, albeit passive, investment by Alphabet's venture arm, GV, in Maze Therapeutics, a common practice for venture capital firms supporting portfolio companies.

Related Party Transactions

• The filing details the beneficial ownership structure where GV 2019, L.P. and GV 2023, L.P. are controlled by GV 2019 GP, L.P. and GV 2023 GP, L.P. respectively, which are ultimately controlled by Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. This establishes a clear related-party relationship among the reporting entities in their ownership of Maze Therapeutics shares.

Stakeholder Impact

• Shareholders may view the continued investment by Alphabet-backed GV entities as a positive indicator of long-term potential and stability for Maze Therapeutics.
• The disclosure provides transparency regarding significant institutional ownership, which can be beneficial for market confidence.

Key Dates

Keywords

Maze Therapeutics, GV, Alphabet Inc., Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Venture Capital